Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 9/20 | 0.51 |
| ▸ | PGR | P06401 | 9/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263576 | 0.87 | NR3C2 (0.50) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL4261432 | 0.86 | NR3C2 (0.49) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL4265400 | 0.85 | NR3C2 (0.53) | NR3C2PGRNR3C1HTR1AHTR1D | |
| SCHEMBL18305164 | 0.83 | PGR (0.47) | NR3C2PGRNR3C1PKMMAPK1 | |
| SCHEMBL13932102 | 0.79 | MAOB (0.48) | NR3C2PGRNR3C1MMP12PKM | |
| SCHEMBL4267840 | 0.79 | MAOB (0.48) | NR3C2PGRNR3C1MMP12PKM | |
| SCHEMBL12116980 | 0.79 | PDE3B (0.53) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL4267366 | 0.79 | MMP12 (0.70) | NR3C2PGRNR3C1MMP12PDE3B | |
| SCHEMBL18305051 | 0.79 | CYP11B1 (0.60) | NR3C2PGRNR3C1PDE3BPDE3A | |
| SCHEMBL4272395 | 0.77 | PGR (0.49) | NR3C2PGRNR3C1MMP12HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | claimed |
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | disclosed |
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | IRM LLC (BM) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054417-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS | NR5A1, ESRRA, NR3C1 | NR3C2 7/4885PGR 46/4885NR3C1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.